Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma

High-risk neuroblastoma remains lethal in about 50% of patients despite multimodal treatment. Recent attempts to identify molecular targets for specific therapies have shown that Neuroblastoma RAS (NRAS) is significantly mutated in a small number of patients. However, few inhibitors for the potentia...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS One
Autors principals: Kiessling, Michael K., Curioni-Fontecedro, Alessandra, Samaras, Panagiotis, Lang, Silvia, Scharl, Michael, Aguzzi, Adriano, Oldrige, Derek A., Maris, John M., Rogler, Gerhard
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2016
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4731059/
https://ncbi.nlm.nih.gov/pubmed/26821351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0147682
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars